ARKGvsXPHETF Comparison
VS
ARK Genomic Revolution ETF (ARKG) belongs to the BioTech & Genomics segment. State Street SPDR S&P Pharmaceuticals ETF (XPH) is part of the US Health Care segment. Both ETFs have the same top 1 sector exposures: Healthcare. ARKG is more expensive with a Total Expense Ratio (TER) of 0.75%, versus 0.35% for XPH. ARKG is up 55.92% year-to-date (YTD) with +$33M in YTD flows. XPH performs worse with 20.76% YTD performance, and +$296M in YTD flows. Run a side-by-side ETF comparison of ARKG and XPH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
ARKG vs XPH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/11/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | ARKG XPH | +2.07%-2.99% | +35.35%+13.04% | +55.92%+20.76% | +73.72%+42.98% | +44.39%+62.03% | -43.98%+50.40% |
| Flows | ARKG XPH | +$57M+$93M | +$127M+$188M | +$33M+$296M | +$51M+$318M | -$523M+$257M | -$2.24B+$264M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | ARKG XPH | +42.98%+22.49% | +43.87%+22.63% | +43.91%+20.52% | +46.35%+20.88% |
| Max drawdown | ARKG XPH | -13.89%-8.78% | -27.52%-11.78% | -46.41%-23.45% | -78.04%-30.87% |
| Max drawdown duration | ARKG XPH | 32d23d | 126d50d | 882d322d | 1818d1452d |
Trading data
ARKG | XPH | |
Last sale 9/11/2026 at 1:30 PM | $45.56 | $67.51 |
| Previous close 09/10/2026 | $45.38 | $68.01 |
| Consolidated volume 09/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
ARKG
is actively managed and doesn’t replicate an indexARKG | XPH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/11/2026 at 1:30 PM
Live
Closed
ARKG | XPH | |
|---|---|---|
| Last price | $45.56 | $67.51 |
| 1D performance | +0.40% | -0.74% |
| AuM | $1.83 B | $588.06 M |
| E/R | 0.75% | 0.35% |
Characteristics
ARKG | XPH | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Ark Investment | State Street Investment Management |
| Benchmark | - | S&P Pharmaceuticals Select Industry Index |
| N° of holdings | 31 | 62 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 2, 2019 | June 19, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
ARKG
USA
88.43%
Other
11.57%
XPH
USA
89.67%
Other
10.33%
Sectors
ARKG
Healthcare
97.99%
Other
2.01%
XPH
Healthcare
92.7%
Other
7.3%
Diversification
ARKG
Total weight of top 15 holdings out of 15
75.55%
XPH
Total weight of top 15 holdings out of 15
32.65%
Top 15 holdings
Data as of July 31, 2026
ARKG
10X Genomics, Inc.
9.41%
Twist Bioscience Corp.
7.74%
Tempus AI, Inc.
6.57%
CRISPR Therapeutics AG
6.30%
Personalis, Inc.
5.48%
Absci Corp.
5.15%
Guardant Health, Inc.
4.75%
Illumina, Inc.
4.75%
Eli Lilly & Co.
4.69%
CareDx, Inc.
4.31%
Natera, Inc.
4.14%
Beam Therapeutics, Inc.
3.78%
Compass Pathways Plc
3.26%
Recursion Pharmaceuticals, Inc.
2.63%
Adaptive Biotechnologies Corp.
2.58%
XPH
Crinetics Pharmaceuticals, Inc.
3.69%
MBX Biosciences, Inc.
3.22%
Amylyx Pharmaceuticals, Inc.
2.29%
Enliven Therapeutics, Inc.
2.24%
Corcept Therapeutics, Inc.
2.22%
Alumis, Inc.
2.13%
Nuvation Bio, Inc.
2.09%
Trevi Therapeutics, Inc.
2.06%
Liquidia Corp.
1.95%
Nektar Therapeutics
1.89%
Amneal Pharmaceuticals, Inc.
1.81%
Bristol Myers Squibb Co.
1.78%
Edgewise Therapeutics, Inc.
1.77%
Omeros Corp.
1.76%
Ligand Pharmaceuticals, Inc.
1.75%
Frequently asked questions about ARKG and XPH
How have the ARKG and XPH ETFs performed in 2026?
As of September 11, 2026, ARKG is up 55.92% year-to-date (YTD), while XPH has returned 20.76%. That puts ARKG better performer ahead so far this year.
Which ETF is attracting more investor money: ARKG or XPH?
Year-to-date, the ARKG ETF saw +$33M in flows, compared to +$296M for XPH.
Which ETF is more volatile: ARKG or XPH?
Over the past year, ARKG had a volatility of 43.87%, while XPH experienced 22.63%.
Which ETF is bigger: ARKG or XPH?
As of September 11, 2026, ARKG holds $1.83 B in assets under management (AUM), while XPH manages $588.06 M.
What sectors do the ARKG and XPH ETFs invest in?
ARKG leans toward sectors like Healthcare. Meanwhile, XPH focuses on Healthcare.
What are the top holdings of the ARKG ETF and XPH ETF?
ARKG top holdings include 10X Genomics, Inc., Twist Bioscience Corp. and Tempus AI, Inc.. XPH holds in its top three: Crinetics Pharmaceuticals, Inc., MBX Biosciences, Inc. and Amylyx Pharmaceuticals, Inc..
Which ETF is more diversified: ARKG or XPH?
ARKG holds 31 securities with 75.55% of its assets in the top 15. XPH has 63 securities and a top 15 weight of 32.65%.
Advertisement
Latest news about ARKG & XPH
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Biotech ETFs – Investing in Health Innovation
July 21, 2022
ARKG
Advertisement
Advertisement
